August 5, 2024

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial

Key Points

Key points are not available for this paper at this time.

Abstract

The EXTEND trial tested the hypothesis that adding comprehensive metastasis-directed therapy (MDT) to chemotherapy would improve progression-free survival (PFS) over chemotherapy alone among patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).

Bookmark

Cite This Study

Ludmir et al. (Mon,) studied this question.

synapsesocial.com/papers/68e5d57fb6db64358756ba71 https://doi.org/https://doi.org/10.1200/jco.24.00081

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial2017 · 678 citations
2Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer2022 · 74 citations
3Oligometastases.1995 · 2,452 citations
4Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND2022 · 21 citations
5Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes2022 · 27 citations

Bookmark